Perceiv AI Joins Johnson & Johnson Innovation–JLABS Global Network to Accelerate Precision Medicine Platform Development

June 21, 2023 | Toronto, Canada

Perceiv AI, an AI-driven precision medicine company, today announced that it has joined Johnson & Johnson Innovation–JLABS, a premier life science incubator program. Perceiv AI will gain access to a variety of resources, including mentorship, and programming to accelerate the development of ForesightTM its multimodal prognostic platform.

Perceiv AI's platform integrates longitudinal clinical data, biomarkers with imaging, fluid biomarkers, and genetics to forecast disease progression in age-related diseases like Alzheimer's. By providing a window into individual patients' disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses.

"We're excited to have the opportunity to build a closer relationship with Janssen through our membership in JLABS," said Dr. Christian Dansereau, CEO and co-founder of Perceiv AI. "Joining this vibrant and innovative community will provide us with world-class resources and expertise of such an innovative company."

To learn more about Perceiv AI, please visit www.perceiv.ai.

About Perceiv AI

Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform to forecast disease progression in age-related diseases like Alzheimer's. By providing a window into individual patients' disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses.